[1]
|
Peptide therapeutics in the management of metastatic cancers
RSC Advances,
2022
DOI:10.1039/D2RA02062A
|
|
|
[2]
|
CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer
Cancer Letters,
2022
DOI:10.1016/j.canlet.2022.215944
|
|
|
[3]
|
Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach
2019
DOI:10.1007/978-981-32-9816-3_2
|
|
|
[4]
|
Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells
Oncotarget,
2018
DOI:10.18632/oncotarget.24580
|
|
|
[5]
|
Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins
Small,
2018
DOI:10.1002/smll.201803601
|
|
|
[6]
|
GPCR Modulation in Breast Cancer
International Journal of Molecular Sciences,
2018
DOI:10.3390/ijms19123840
|
|
|
[7]
|
Quinic Acid‐Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins
Small,
2018
DOI:10.1002/smll.201803601
|
|
|
[8]
|
Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
Cancer Medicine,
2017
DOI:10.1002/cam4.1085
|
|
|
[9]
|
Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
Cancer Medicine,
2017
DOI:10.1002/cam4.1085
|
|
|
[10]
|
Seek & Destroy , use of targeting peptides for cancer detection and drug delivery
Bioorganic & Medicinal Chemistry,
2017
DOI:10.1016/j.bmc.2017.08.052
|
|
|
[11]
|
CXCR4 and CCR7: Two eligible targets in targeted cancer therapy
Cell Biology International,
2016
DOI:10.1002/cbin.10631
|
|
|
[12]
|
Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs
Scientific Reports,
2016
DOI:10.1038/srep35765
|
|
|
[13]
|
CXCR4 and CCR7: Two eligible targets in targeted cancer therapy
Cell Biology International,
2016
DOI:10.1002/cbin.10631
|
|
|
[14]
|
Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs
Scientific Reports,
2016
DOI:10.1038/srep35765
|
|
|
[15]
|
Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancers
Oncotarget,
2015
DOI:10.18632/oncotarget.4615
|
|
|